Full Text | PDF

Share on facebook Share on tweeters Share on linkedin Share on googleplus

Theranostics 2020; 10(17):7635-7644. doi:10.7150/thno.44229 This issue Cite

Research Paper

The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma

Lu Yang1#, Jing Zhang2#, Guangjian Yang1, Haiyan Xu3, Jing Lin4, Lin Shao4, Junling Li1, Changyuan Guo2, Yanru Du2, Lei Guo2, Xin Li2, Han Han-Zhang4, Chenyang Wang4, Shannon Chuai4, Junyi Ye4, Qiaolin Kang4, Hao Liu4, Jianming Ying2✉, Yan Wang1✉

1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
2. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
3. Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
4. Burning Rock Biotech, Guangzhou, 510300, China.
#L. Yang and J. Zhang contributed equally to this article.

✉ Corresponding authors: Yan Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Tel: +86 13911793771, Fax: +86 106773 More

Citation:
Yang L, Zhang J, Yang G, Xu H, Lin J, Shao L, Li J, Guo C, Du Y, Guo L, Li X, Han-Zhang H, Wang C, Chuai S, Ye J, Kang Q, Liu H, Ying J, Wang Y. The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma. Theranostics 2020; 10(17):7635-7644. doi:10.7150/thno.44229. https://www.thno.org/v10p7635.htm
Other styles

File import instruction

Abstract

Graphic abstract

Current NCCN guidelines do not recommend the use of adjuvant chemotherapy for stage IA lung adenocarcinoma patients with R0 surgery. However, 25% to 40% of patients with stage IA disease experience recurrence. Stratifying patients according to the recurrence risk may tailor adjuvant therapy and surveillance imaging for those with a higher risk. However, prognostic markers are often identified by comparing high-risk and low-risk cases which might introduce bias due to the widespread interpatient heterogeneity. Here, we developed a scoring system quantifying the degree of field cancerization in adjacent normal tissues and revealed its association with disease-free survival (DFS).

Methods: We recruited a cohort of 44 patients with resected stage IA lung adenocarcinoma who did not receive adjuvant therapy. Both tumor and adjacent normal tissues were obtained from each patient and subjected to capture-based targeted genomic and epigenomic profiling. A novel methylome-based scoring system namely malignancy density ratio (MD ratio) was developed based on 39 patients by comparing tumor and corresponding adjacent normal tissues of each patient. A MD score was then obtained by Wald statistics. The correlations of MD ratio, MD score, and genomic features with clinical outcome were investigated.

Results: Patients with a high-risk MD ratio showed a significantly shorter postsurgical DFS compared with those with a low-risk MD ratio (HR=4.47, P=0.01). The MD ratio was not associated with T stage (P=1), tumor cell fraction (P=0.748) nor inflammatory status (p=0.548). Patients with a high-risk MD score also demonstrated an inferior DFS (HR=4.69, P=0.039). In addition, multivariate analysis revealed EGFR 19 del (HR=5.39, P=0.012) and MD score (HR= 7.90, P=0.01) were independent prognostic markers.

Conclusion: The novel methylome-based scoring system, developed by comparing the signatures between tumor and corresponding adjacent normal tissues of individual patients, largely minimizes the bias of interpatient heterogeneity and reveals a robust prognostic value in patients with resected lung adenocarcinoma.

Keywords: stage IA lung adenocarcinoma, disease-free survival, methylome-based malignancy density, genomic and epigenetic signatures, recurrence

Citation styles

APA
Yang, L., Zhang, J., Yang, G., Xu, H., Lin, J., Shao, L., Li, J., Guo, C., Du, Y., Guo, L., Li, X., Han-Zhang, H., Wang, C., Chuai, S., Ye, J., Kang, Q., Liu, H., Ying, J., Wang, Y. (2020). The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma. Theranostics, 10(17), 7635-7644. https://doi.org/10.7150/thno.44229.

ACS
Yang, L.; Zhang, J.; Yang, G.; Xu, H.; Lin, J.; Shao, L.; Li, J.; Guo, C.; Du, Y.; Guo, L.; Li, X.; Han-Zhang, H.; Wang, C.; Chuai, S.; Ye, J.; Kang, Q.; Liu, H.; Ying, J.; Wang, Y. The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma. Theranostics 2020, 10 (17), 7635-7644. DOI: 10.7150/thno.44229.

NLM
Yang L, Zhang J, Yang G, Xu H, Lin J, Shao L, Li J, Guo C, Du Y, Guo L, Li X, Han-Zhang H, Wang C, Chuai S, Ye J, Kang Q, Liu H, Ying J, Wang Y. The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma. Theranostics 2020; 10(17):7635-7644. doi:10.7150/thno.44229. https://www.thno.org/v10p7635.htm

CSE
Yang L, Zhang J, Yang G, Xu H, Lin J, Shao L, Li J, Guo C, Du Y, Guo L, Li X, Han-Zhang H, Wang C, Chuai S, Ye J, Kang Q, Liu H, Ying J, Wang Y. 2020. The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma. Theranostics. 10(17):7635-7644.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2025 Ivyspring International Publisher. Terms of use